Ionis Pharmaceuticals Inc

IONS

72.700USD

+3.020+4.33%

Close 03/25, 16:00（ET）Quotes delayed by 15 min

Ionis Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

36 / 391

Overall Ranking

123 / 4547

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Ionis Pharmaceuticals Inc Highlights

StrengthsRisks

Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 19.81% year-on-year.

Undervalued

The company’s latest PE is -30.50, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 176.89M shares, decreasing 4.55% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 2.04K shares of this stock.

Analyst Rating

Based on 23 analysts

Buy

Current Rating

92.450

Target Price

+30.60%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Ionis Pharmaceuticals Inc is 6.16, ranking 282 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 203.33M, representing a year-over-year decrease of 10.26%, while its net profit experienced a year-over-year decrease of 119.83%.

Score

Industry at a Glance

Previous score

6.16

Change

0



Financials

4.45

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.21

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

6.43

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.58

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Ionis Pharmaceuticals Inc is 7.20, ranking 148 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -30.50, which is -71.94% below the recent high of -8.56 and -76.39% above the recent low of -53.80.

Score

Industry at a Glance

Previous score

7.20

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 36/391

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Ionis Pharmaceuticals Inc is 8.09, ranking 162 out of 391 in the Biotechnology & Medical Research industry. The average price target is 87.00, with a high of 110.00 and a low of 46.00.

Score

Industry at a Glance

Previous score

8.09

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Ionis Pharmaceuticals Inc is 7.07, ranking 126 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 80.67 and the support level at 66.82, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.69

Change

0.38

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-25

The current institutional shareholding score of Ionis Pharmaceuticals Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 109.21%, representing a quarter-over-quarter increase of 2.27%. The largest institutional shareholder is The Vanguard, holding a total of 16.40M shares, representing 9.93% of shares outstanding, with 3.34% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

23.69M

+0.19%

Capital World Investors

17.96M

+41.17%

The Vanguard Group, Inc.

Star Investors

16.44M

-1.41%

T. Rowe Price Investment Management, Inc.

13.16M

-18.02%

BlackRock Institutional Trust Company, N.A.

8.45M

-3.12%

Wellington Management Company, LLP

6.59M

+3.83%

Two Sigma Investments, LP

3.65M

-18.11%

Bellevue Asset Management AG

6.24M

-20.49%

State Street Investment Management (US)

4.39M

-3.13%

Geode Capital Management, L.L.C.

3.07M

+6.06%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Ionis Pharmaceuticals Inc is 8.34, ranking 5 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.43. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Ionis Pharmaceuticals Inc

IONS

7.49 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

AnaptysBio Inc

ANAB

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.31 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Madrigal Pharmaceuticals Inc

MDGL

8.30 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.23 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment